secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERUS CORP (CERS)
CIK:        0001020214
Form:       8-K
Filed at:   2022-02-22T23:59:59+00:00
Accession:  0001193125-22-048529
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cerus Q4 revenue $50.1M (+49% YoY); reiterates FY2022 product revenue guidance $157-164M
--------------------------------------------------------------------------------

- Q4 product revenue $39.9M (+41% YoY); net loss narrowed to $9.1M ($0.05/sh) from $14.4M.
- FY2021 total revenue $159.5M (+40% YoY); product revenue $130.9M (+42% YoY).
- FY2022 product revenue guidance reaffirmed at $157-164M, representing 20-25% growth.
- Two blood centers obtained BLA approvals for INTERCEPT Fibrinogen Complex (IFC), enabling interstate sales.
- Cash, equivalents and short-term investments $129.4M at Dec 31, 2021; net cash used in ops $33.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1020214/000119312522048529/0001193125-22-048529-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1020214/000119312522048529/d317573d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-048529

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer